The art of saying no in clinical trials goes beyond simply delivering news; it involves maintaining relationships and ...

The conundrum of missing data vs. inter-rater variability.

Tips and best practices for empowering professionals to become change agents in their institutions, including clinical trials ...

Are New Medicines Being Developed to Meet the Needs of the Ever-Ageing Population?

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve ...

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Patil, vice president, digital innovation, IQVIA, ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy Peter Ronco, CEO, Emmes, discusses the number of ...

Session explores innovation in operationalizing clinical trials and how challenges with adoption can be addressed.

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Peter Ronco, CEO, Emmes, provides advice to small biopharma companies looking to scale their clinical programs without ...

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Tenaerts, chief scientific officer, Medable, highlights ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, CEO, CluePoints, discusses goals of the SCOPE Summit and CluePoints' evolving approach to risk detection.

Continuing on Day 2 of this year’s SCOPE Summit in Orlando, a noteworthy session examined ways to better recognize and ...